Key Takeaways Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to ...